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Abstract 
 
Cervical cancer (CC) is a common malignancy in women and a major cause of cancer- related 
mortality globally. Some novel biomarkers may enable the early diagnosis and monitoring of 
CC. MicroRNAs are small noncoding RNAs that control gene translation at a post 
transcriptional level.  Hence the deregulation of these molecules can cause many diseases. 
There appears to be an association between aberrant miRNA expression and CC, but the 
molecular mechanisms involved in the development of CC remain unknown. The upregulation 
of some circulating miRNAs, e.g. miRNA-20a, miRNA-203, miRNA-21, miRNA-205, 
miRNA-218, and miR-485-5, as well as tissue specific-miRNAs, e.g. miR-7, miR-10a, miR-
17-5p, miR-135b, miR-149 and miR-203 has been found in patients with CC. There is also 
growing evidence for the importance of miRNAs in the development of drug-resistance. This 
review therefore highlights recently published preclinical and clinical investigation performed 
on tissue-specific and circulating miRNAs, as potential biomarkers for the detection of patients 
at early stages of CC, in the prediction of prognosis, and monitoring of their response to 
therapy. 
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Introduction: 
Cervical cancer (CC) is the fourth most common cancer in women and a major cause of cancer- 
related mortality. A comprehensive approach that includes early diagnosis of CC can reduce 
the high mortality rate of this disease globally (1). Thus the identification of novel prognostic 
and predictive biomarkers is an important factor in the management of patients during therapy 
and in the early diagnosis of cervical cancer. 
MicroRNAs (miRNAs) are endogenous single-stranded noncoding RNAs that control gene 
expression at post-transcriptional level by means of miRNA-mRNA interactions. These 
interactions lead to degradation or inhibition of mRNA translation (2). MicroRNAs are of great 
importance in all biological processes, thus abnormal expression of these molecules has been 
found to be associated with several conditions. In 2002 it was first reported that miRNAs are 
associated with cancer and attention was drawn to these molecules because of their potential 
value as biomarkers(3). MicroRNAs can circulate in several forms:  freely in blood, 
encapsulated in exosomes or associated with protein complexes. Studies have shown a 
deregulation of their expression in cervical cancer patients(4). The expression pattern of 
miRNAs in the tumor tissue of cervical cancer patients also differed from healthy subjects (5). 
Other studies have evaluated the role of miRNAs as therapeutic targets. This requires further 
comprehensive studies. 
There has been a recent increasing interest in the miRNAs in relation to cancer diagnosis.  
 
Circulating microRNAs in cervical cancer 
MiRNAs circulate in the bloodstream, often within micro vesicles or protected by binding 
proteins in blood. They can be chemically altered (e.g., methylation), making them highly 
resistant to decay by ribonuclease and may therefore be potential biomarkers due to their 
stability, and ease of measurement. However, the source and detailed mechanisms of cellular 
release of circulating miRNAs remains largely unknown. Studies have shown that miRNAs 
can be released into the circulation from cells by apoptotic and necrotic cell death. MiRNAs 
can also be secreted by cancer cells, and this may enhance tumor growth and spread, and are 
also released by numerous other cell types such as blood cells, immune effector cells, and other 
cells involved in tumor attack and inflammatory response. Zhao et al,  demonstrated that there 
are high serum concentrations of miRNA-20a and miRNA-203 in patients with CC compared 
to healthy subjects (6). Ma and coworkers have reported that miRNA-205 could also be a 
promising biomarker as its serum levels are increased in patients with cervical cancer (7). 
MiRNA-21 could play a role in the diagnosis of cervical cancer metastasis. Future studies are 
needed to explore whether a therapeutic intervention can be developed based on this finding 
that could be used to block lymph node metastasis in cervical cancer. (8) Yu and collaborators 
have reported that the expression of miRNA-218 alters according to the different stages of 
cancer: cancer pathological pattern and lymph node metastasis, and so it has been proposed 
that miRNA-218 could be used in the cancer staging process (9). This view is partially 
supported by Nagamitsu et al (2015), who have shown an increased level of serum miRNA-
1290 along with the stage of CC. On the other hand, the authors did not observe any significant 
relationship between miRNA expression level and lymph node metastasis. This research also 
provides evidence of a much higher level of miR-485-5p, miR-1246, miR-1275 and miR-1290 
among cervical cancer patients in comparison with healthy individuals (10). 
 
 
Exosomes and miRNAs 
Exosomes are nano-sized (30–100 nm) membrane extracellular vesicles, that originate from 
numerous types of cells, including: tumor cells, reticulocytes, neurons, and immune cells in 
physiological and pathological conditions. Exosomes comprise a lipid bilayer containing 
ceramides, phosphoglycerides, cholesterols, and sphingolipids. Since exosomes originate from 
cells, they contain several cellular component, that include: carbohydrates, lipids, proteins, 
peptides, DNAs, and RNAs (Figure 1). Exosomes are present in most body fluids, including: 
saliva, blood, breast milk, and urine. Once released, exosomes bind to other cells via receptor-
ligand mechanisms, or deliver intra-exosomal elements without specific binding. Exosomes 
contain genetic information of their cellular source, and circulate throughout the circulatory 
system. Therefore, the biomolecules that they contain, such as miRNAs may be potentially 
useful biomarkers, allowing non-invasive disease diagnosis (2).  
Numerous studies have shown that the components secreted by exosomes from cancer cells are 
associated with tumor promotion and malignancy. According to Liu and colleagues, exosomal 
levels of miRNA-21 and miRNA-146a were higher in samples from patients with cervical 
cancer compared to those who were HPV-positive, or HPV-negative normal counterparts. 
Furthermore, miRNA-21 and miRNA-146a were expressed at a higher levels in exosomes from 
HPV-positive patients than in HPV-negative subjects.(11) Similarly, as noted by Honegger et 
al, expression of E6/E7 oncogenes in HPV-positive cancer cells could affect the exosomal 
expression level of 7 cervical cancer-associated miRNAs, with a down-regulation of let-7d-5p, 
miR-20a-5p, miR-378a-3p, miR-423-3p, miR-7-5p, and miR-92a-3p and up-regulation of 
miR-21-5p (12). A recent review concluded that miRNA-7, miRNA-99, miRNA-378 and the 
miRNA 17-92 families of miRNAs are the major exosomal miRNAs that are altered in HPV 
associated cancers, particularly CC (13). 
 
Tissue specific MiRNAs in cervical cancer 
Different miRNA families have evolved to provide a diverse range of transcriptional products. 
Sequence maintenance and RNA binding-proteins have evolved together to gain a final fine-
tuning gene adjustment in various cells and tissues Several miRNAs have been identified that 
are related to CC growth. For instance, miR-7, miR-10a, miR-17-5p, miR-19a and miR-19b, 
miR-21, miR-125b and miR-138, each regulates tumorigenic, or tumor suppressor factors: 
XIAP, CHL1, TP53INP1, CUL5, PDCD4, PIK3CD, and hTERT respectively. These factors 
are negatively regulated by the above miRNAs apart from CUL5. (14) Furthermore, Li et al 
have suggested that miRNA-100 is expressed at higher levels in low-grade CIN samples 
compared to high-grade CIN . MiRNA-100 is a negative regulator of PLK1, whose 
overexpression is often observed in tumor cells. Therefore, the adverse impact of miRNA-100 
on cell growth would be justifiable. (15) In an investigation into cervical cancer-associated 
miRNAs, Pereira et al found that miR-21, miR-135b, miR-223, miR-301b and miR-135b are 
over-expressed miRNAs, that could be useful to diagnose cervical cancer (16). Lee et al has 
suggested that miR-199-s, miR-9, miR199a, miR-199a, miR-199b, miR-145, miR-133a, miR-
133b, miR-214 and miR-127 are the most significantly up-regulated miRNAs and miR-149 
and miR-203 as two down-regulated miRNAs in tumor samples. In order to understand the 
effect of miRNA-199a expression level on cell growth, Lee et al transfected anti-miRNA-199a 
into the SiHa and ME-180 tumour cell lines, and observed a significant reduction in miRNA-
199a expression levels, suggesting a cancer growth blocker function of anti-miRNA-199a. (17) 
Reshmi et al have noted that some miRNAs (miR-126, miR-143, miR-145, miR-218, and miR-
424) are downregulated and others upregulated (miR-15b, miR-16, miR-146a, miR-155, and 
miR-223) in CC tissues. They also proposed that diﬀerent miRNA species could have a tumor 
suppressive or oncogenic function in CC tissues. (18) For instance, it has been shown that 
miRNA-143 and miRNA-145 act as a suppressive factor for tumor progression, whereas 
overexpression of miRNA-146a has a tumorogenic effect and reduce cervical cancer cell 
doubling time (19). Granados-López conclude that miR-10a-5p and miR-10b-5p play an 
adverse role in cervical cancer development. MiR-10a-5p behaves as an oncogene and its 
expression level increases from stage 1 to stage 4 of cervical cancer. Whereas, miR-10b-5p has 
a tumor-suppressor function as a result of its ability to down-regulate Homeobox A1 (HOXA1). 
(20) A further opposing function in one family of miRNAs has been reported between miR-
15a-3p and miR-15a-5p (21). In addition, miR-15 and miR-16 have been placed in the group 
of cancer growth blocker miRNAs, as their overexpression could affect negatively on HeLa 
cells’ G1-S cycle (21). A recent study by Lopez et al demonstrated that miRNA-1-3p is an anti-
oncomiRNA; as it regulates glucose-6-phosphate dehydrogenase (G6PD) level, it contributes 
to programmed cell death and a reduction in cancer growth (22).  
MiRNAs as Therapeutic Targets 
Many clinical trials have investigated the relationship between miRNA and different disease 
such as malignances, asthma, psychotic depression, Irritable bowel syndrome, diabetes 
mellitus, and cardiovascular disease (23-27). Several clinical studies are in progress on the 
effect of miRNA on a variety of cancers like prostate, breast, melanoma, skin, lung cancers, 
etc (28-32). In relation to these studies, scientists have focused on the use of miRNAs as a 
diagnostic, predictive, or prognostic biomarkers for cancer treatment. For example, in a recent 
study, Hagstrom AD and Denham have shown miRNA expression profile is different between 
high and low responders to resistance training in breast cancer patients (33). In the first-in-man, 
phase 1, open-label, dose-escalation study, scientists examine the Safety and activity of 
microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma. They 
could find The acceptable safety profile and early signs of activity of TargomiRs in patients 
with malignant pleural mesothelioma (34) in the first-in-human, phase I study, which assessed 
the maximum tolerated dose (MTD), safety, pharmacokinetics, and clinical activity of MRX34, 
a liposomal miR-34a, in patients with advanced solid tumors, results have been shown, MRX34 
treatment with dexamethasone premedication was associated with acceptable safety and 
showed evidence of proloferation activity in a subset of patients with advanced solid tumors 
(35).  
. In CC, the most common treatments are surgery, radiotherapy, chemotherapy (36). Mou et al 
have reported that miR-148b is a tumor suppressor of CC, that works by inducing G1/S-phase 
cell cycle arrest and apoptosis in a caspase-3-dependent manner. Hence, overexpression of 
miR-148b may be a new therapeutic approach for CC (37). Wand and colleagues have found 
that miR-214 is frequently downregulated in tumor tissues chiefly in CIN III. MiR-214 can 
prevent cell migration and invasion and enhanced drug sensitivity in cervical cancer cells (36). 
Zhou et al have shown that miR-138 expression is downregulated in cervical cancer and is 
negatively associated with advanced FIGO (International Federation of Gynecology and 
Obstetrics) stage and lymph node metastasis. In other words, miR-138 functions as a tumor 
suppressor in cervical cancer by suppressing cancer growth, preventing cell migration and 
increasing apoptosis (38). Another study has shown that miR-195 inhibits CC cell proliferation, 
invasion and migration (39). Therefore miR-195 may be a potential target for the treatment of 
CC (39). Su and colleagues have reported that patients with cervical cancer, who have a 
decreased expression of miR-34a and miR-206, have an increased risk of lymph node 
metastasis, advanced stage and histological grade and shorter survival in the study (40). 
MicroRNA 21 is recognized as the direct target gene of GAS5 and over expression of GAS5 
prevents cervical cancer cell growth, invasion and migration according to Wen et al (41). Li 
and colleagues have shown that miR-138 is a potential prognostic biomarker and miR-138 
functions as tumor suppressor in CC (42). Li et al have reported that miR-378 is a novel 
therapeutic strategy in CC (43). MiR-30e can suppress the proliferation and invasion of CC 
cells through targeting mRNA and it can be a new therapeutic target for CC in the future (44). 
Wang et al have shown that overexpression of miR-34a-5p prevented proliferation of CC cells 
and promoted apoptosis of these cells by down-regulating Bcl-2 expression (45). Another study 
found that miR-187 inhibited the proliferation and promoted apoptosis of cervical cancer cells 
and it also inhibited the growth of CC cells in nude mice in an in vivo experiment (46).  
Conclusion: 
CC is a major cause of cancer-related mortality in women. Thus identification of novel 
prognostic and predictive biomarkers is essential in management of patients during the therapy 
and early diagnosis of cancer. Numerous recent studies have highlighted the predictive and 
therapeutic role of miRNAs in cervical cancer. However, there is a need for more 
comprehensive studies to light up the clinical utility of these biomarkers.  
Many studies have evaluated different types of circulating or tissue specific miRNAs and their 
role in diagnosis of cervical cancer. The expression level of some of these differs significantly 
in CC patients from healthy individuals, and thus they can be used as biomarkers to diagnose 
cancer in early stages. Many studies support the therapeutic potential of miRNAs in cervical 
cancer. MicroRNAs can suppress the proliferation and invasion of cancer cells and as a result 
prevent metastasis. It is also stated that these markers can induce apoptosis of the cancer cells. 
On the other hand, some miRNAs are oncogenes and increase simultaneously with the stages 
of cancer. The studies of microRNAs are very promising and future studies will simplify the 
diagnosis and treatment of cancer. Understanding of molecular pathways of miRNAs that 
regulate the development of CC can provide an insight into their future clinical application. 
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Figure legend 
Figure 1. Exosomes and microRNAs. Exosomes contain genetic information of their cellular source, 
and circulate throughout body, indictaing its values as non-invasive biomarkers 
 
 
 
